Global Information Lookup Global Information

Alnylam Pharmaceuticals information


Alnylam Pharmaceuticals, Inc.
Company typePublic
Traded as
  • Nasdaq: ALNY
  • Russell 1000 component
IndustryPharmaceutical
Founded2002; 22 years ago (2002)
HeadquartersCambridge, Massachusetts, U.S.
Key people
Yvonne Greenstreet (CEO)
RevenueIncrease US$1.83 billion (2023)
Decrease US$1.04 billion (2022)[1]
Number of employees
2,100 (2023)[2]
Websitealnylam.com

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.[5]

  1. ^ "Alnylam Pharmaceuticals Inc. Annual Income Statement". MarketWatch. 12 August 2023.
  2. ^ "Alnylam Pharmaceuticals: Number of Employees 2006-2021". www.macrotrends.net.
  3. ^ "Alnylam Pharmaceuticals Inc (ALNY) Quote - XNAS | Morningstar. Alnylam Pharmaceuticals Inc's Company Profile. Business Description". www.morningstar.com. Retrieved 15 May 2022.
  4. ^ "ALNY | Alnylam Pharmaceuticals Inc. Company Profile & Executives - WSJ". www.wsj.com. Retrieved 15 May 2022.
  5. ^ "Most Innovative Growth Companies #100 Alnylam Pharmaceuticals". Forbes. May 2016. Retrieved September 22, 2016.

and 27 Related for: Alnylam Pharmaceuticals information

Request time (Page generated in 0.8482 seconds.)

Alnylam Pharmaceuticals

Last Update:

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference...

Word Count : 1743

Small interfering RNA

Last Update:

development of RNAi therapy for humans. Alnylam Pharmaceuticals, Sirna Therapeutics and Dicerna Pharmaceuticals are few of the companies still working...

Word Count : 6760

Takeda Pharmaceutical Company

Last Update:

licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies...

Word Count : 2769

Arbutus Biopharma

Last Update:

of Inex Pharmaceuticals in 2007. Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005...

Word Count : 1112

RNA interference

Last Update:

in 2018 with the siRNA drug patisiran, developed by Alnylam Pharmaceuticals. Dicerna Pharmaceuticals, Persomics, Sanofi and Sirna Therapeutics also worked...

Word Count : 15447

Amy Weinfeld Schulman

Last Update:

biotech start-ups. She also chairs the Board of Directors for Alnylam Pharmaceuticals (NASDAQ: ALNY) and ByHeart, and represents Polaris as a director...

Word Count : 764

Patisiran

Last Update:

Transthyretin-Mediated Amyloidosis" (PDF). Alnylam Pharmaceuticals. Archived (PDF) from the original on 9 October 2021. "Alnylam Pharmaceuticals Reports Fourth Quarter and...

Word Count : 952

List of largest biomedical companies by market capitalization

Last Update:

"• Top biotech and pharmaceutical companies market value 2015 - Statistic". Statista. "ALNY Stock Price | Alnylam Pharmaceuticals Inc. Stock Quote (U...

Word Count : 174

List of pharmaceutical companies

Last Update:

Grünenthal (1946– ) GSK (2000– ) Guangzhou (1951– ) GW Pharmaceuticals (subsidiary of Jazz Pharmaceuticals; 1998– ) Hanhong (2012– ) Hanmi (1973– ) Hansoh (1995–...

Word Count : 1369

Yvonne Greenstreet

Last Update:

executive. She is chief operating officer of Alnylam Pharmaceuticals, and from 1 January 2022 Alnylam's CEO. She is one of a small number of Black women...

Word Count : 348

Biotechnology industry in Boston

Last Update:

Therapeutics Aderis Pharmaceuticals Agios Pharmaceuticals Alkermes Alnylam Pharmaceuticals Amgen Alzheon Deciphera Pharmaceuticals Editas Medicine Intellia...

Word Count : 1794

Ionis Pharmaceuticals

Last Update:

confidence by the market in antisense technology. In 2007, Isis and Alnylam Pharmaceuticals, which focuses on RNA interference, formed a 50/50 joint venture...

Word Count : 1420

Roche

Last Update:

IL-2 receptor agonist program. In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension...

Word Count : 5233

Phillip Allen Sharp

Last Update:

of Alnylam Pharmaceuticals; advisor and investor at Longwood and Polaris Venture Funds; a member of the Boards of Directors at Syros Pharmaceuticals and...

Word Count : 2301

List of INSEAD alumni

Last Update:

Julie Meyer, Author and Businesswoman Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals Philippe Harache, Former Deputy CEO, Eurocopter Franz Humer, Chairman...

Word Count : 751

Antisense therapy

Last Update:

developed by Ionis Pharmaceuticals and licensed to Akcea Therapeutics. Patisiran (sold under Onpattro) was developed by Alnylam Pharmaceuticals, and also approved...

Word Count : 2214

Lumasiran

Last Update:

priority review voucher. The FDA granted the approval of Oxlumo to Alnylam Pharmaceuticals, Inc. Lumasiran is available under the UK Early Access to Medicines...

Word Count : 1171

Margaret Hamburg

Last Update:

for Health Security. Hamburg joined the board of directors for Alnylam Pharmaceuticals in 2018. In 2020, Hamburg participated in the strategic framework...

Word Count : 3498

William Rastetter

Last Update:

Rastetter has been described as an "omnipotent biotech force" and by Alnylam Pharmaceuticals CEO John Maraganore as an "industry legend" who has deep biotechnology...

Word Count : 2503

Whitehead Institute

Last Update:

property developed at the institute, such as Alnylam Pharmaceuticals, Sanofi Genzyme, Ironwood Pharmaceuticals, Rubius Therapeutics, and Verastem. In 2019...

Word Count : 1201

Inclisiran

Last Update:

subsidiary of Novartis, which licensed the rights to inclisiran from Alnylam Pharmaceuticals. The effectiveness of inclisiran was studied in three randomized...

Word Count : 1744

Biodefense

Last Update:

Cleveland BioLabs Incorporation, Achaogen (bankrupt in 2019), Alnylam Pharmaceuticals, Avertis, Xoma Corporation, Dynavax Technologies Incorporation...

Word Count : 2937

David Bartel

Last Update:

regulatory phenomena. Bartel is a founder and a scientific advisor of Alnylam Pharmaceuticals, a company started in 2002 to advance “RNAi (RNA interference)...

Word Count : 840

John Maraganore

Last Update:

executive officer and a member of the board of directors at Alnylam Pharmaceuticals. At Alnylam, he led the company’s pioneering efforts to advance RNA interference...

Word Count : 840

Michael Bonney

Last Update:

appointed the chairman of the board of Alnylam Pharmaceuticals in December 2015. His chairmanship at Alnylam was coupled with a total compensation of...

Word Count : 1679

Sanofi

Last Update:

and Alnylam Pharmaceuticals, a US biotechnology company developing RNAi therapeutics, announced that Genyzme would invest $700 million in Alnylam. Under...

Word Count : 8728

Russell 1000 Index

Last Update:

Financials Property & Casualty Insurance Ally Financial ALLY Financials Alnylam Pharmaceuticals ALNY Health Care Alphabet (Class A) GOOGL Communication Services...

Word Count : 231

PDF Search Engine © AllGlobal.net